+34 9340006100 -ext. 437807-info@nanbiosis.com

Nanbiosis

You are here : Home / Archive for "cancer"

U1. Protein Production Platform Unit (PPP)

Ciber bbn

U1. Protein Production Platform (PPP)

U1. PPP logo IBB UAB

Order request
U1 PPP-Insect cells-Baculovirus as cell factoriesU1 PPP-Insect cells-Baculovirus as cell factories
U1 PPP-7L Bioreactor for protein productionU1 PPP-7L Bioreactor for protein production
U1 PPP–AKTA Purifier equipment for protein purificationU1 PPP–AKTA Purifier equipment for protein purification

Description

The PPP Unit is at the Institute of Biotechnology and biomedicine of the Autonomous University of Barcelona (IBB-UAB) and counts with the necessary facilities for the design, production and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, leaded by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer an “tailored” service for the design, production and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic,X-ray crystallography, and the Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.

Counts with a laboratory perfectly equipped for the bioproduction of proteins, other with all the necessary equipment for the molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.

The PPP Unit has implemented the ISO9001 certification forstandard quality control system.

IQNet ISO 9001:2015 Certification PPP

AENOR ISO 9001:2015 Certification PPP

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U1. Services & Rates

Equipments

Active projects

Title Fundin: Organism Call: Funding source Role
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017		 Coordinator

Other projects

Ref Title Funding Organism Unit Role
PI15/00272 Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer. Instituto de Salud Carlos III Participant
BIO2013-41019-P ENGINEERING OF PROTEIN NANOPARTICLES FOR THE DIRECT DELIVERY OF THERAPEUTIC PROTEINS AND NUCLEIC ACIDS MINECO Participant
2014SGR-132 Basic and Applied Microbiology AGAUR Participant
BIO2016-76063-R DEVELOPMENT OF NONOSTRUCTURED PROTEIN TOXINS AND POISONS FOR THE TREATMENT OF CXCR4 + CANCERES MINECO Working package
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant
Marato 416/C/2030TV32013-132031 Genotoxic nanoparticles targeting colorectal cancer stem cells Marato TV3 Participant

Publications


2016

  • Corchero J.L.. Eukaryotic aggresomes: from a model of conformational diseases to an emerging type of immobilized biocatalyzers. Applied Microbiology and Biotechnology. 2016;100(2):559-569.
  • Saccardo P., Corchero J.L., Ferrer-Miralles N.. Tools to cope with difficult-to-express proteins. Applied Microbiology and Biotechnology. 2016;:1-9.
  • Torrealba D., Seras-Franzoso J., Mamat U., Wilke K., Villaverde A., Roher N. et al. Complex particulate biomaterials as immunostimulant-delivery platforms. PLoS ONE. 2016;11(10)
  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.
  • Serna N., Cespedes M.V., Saccardo P., Xu Z., Unzueta U., Alamo P. et al. Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016;12(5):1241-1251.
  • Rueda F., Gasser B., Sanchez-Chardi A., Roldan M., Villegas S., Puxbaum V. et al. Functional inclusion bodies produced in the yeast Pichia pastoris. Microbial Cell Factories. 2016;15(1)
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova I et al. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models.Nanomedicine : nanotechnology, biology, and medicine. 2016;12(7)
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U1

28 Sep

Nanoligent raised €2.8 M and completed Seed round financing with support of i&i Biotech Fund

September 27th 2022 – Nanoligent SL, a Spanish biotech company specialized in the development of cancer treatments based on unique protein conjugates, today announces the completion of a Seed financing round of total € 2.8 M. The final closing of the Seed round consists of € 1 M investment by i&i Biotech Fund I (i&i Bio), an early-stage Life Science fund with teams in Luxemburg and Prague which is backed by the European Investment Fund. i&i Bio joined previous Nanoligent investors, Italian Angels for Growth, the largest network of business angels in Italy, and AVANTECA Partners, a Swiss privately held[...]

16 Aug

Two NANBIOSIS Units of CIBER-BBN at UAB, one of the 300 best universities in the world, according the Shanghai Ranking

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the Autonomous University of Barcelona among the elite of the 300 best universities in the world. This indicator organizes up to 20,000 university centers worldwide,based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings Two of NANBIOSIS Units created by UAB and CIBER-BBN are part of this university: U1 Protein Production Platform (PPP), led by Toni Villaverde, Neus Ferrer and Mercedes Marquez, offer an “tailored” service for the design,[...]

25 Jun

How engineered protein helps Nanomedicine againts Cancer

The use of protein nanoparticles as biomaterials have been rising in recent years due to their characteristics: high biocompatibility, structural versatility, biodegradability and plasticity of design. We can later incorporate peptide ligands for specific targeting as fusion proteins and use these nanoparticles for targeted nanomedicine. However, not all proteins can be used as scaffolds for targeted drug delivery, as they need to meet certain criteria. First, it is crucial that the proteins used as a scaffold allow site-specific drug conjugation. The stability and proteolysis resistance of these proteins is also important to remain assembled during the bloodstream circulation. In addition,[...]

02 May

Wide representation of NANBIOSIS research in NALS 2022 and best Oral Presentation to Eloi Parladé

During the last 27-29 April, the 3rd International Conference on Nanomaterials Applied to Life Sciences 2022 (NALS 2022) has taken place in the Excellence Campus of Universidad de Cantabria in Santander (Spain), organized by the University of Cantabria and Institute Valdecilla-IDIVAL. NALS 2022 has been a multidisciplinary conference series sharing new results and ideas in the fields of biosensors, lab on a chip, drug delivery nanopharmacy. nanobiotechnology, intelligent nanomaterials, magnetic materials, nanotoxicity, antimicrobials, novel applications of 3d bioprinting and nanoimaging. NANBIOSIS has been represented at this edition by members of several of its units, among them we must highlight the set of four ora[...]

28 Feb

Fabry Desease in the Rare Disease Day: A New Hope

WHY DO CELEBRATE TODAY THE INTERNATIONAL #RareDiseaseDay? 29 of February is a ‘rare’ date and February, a month with a ‘rare’ number of days, has become a month to raise awareness about rare diseases and their impact on patients’ lives.  Since 2008 thousands of events happen every year all around the world and around the last day of February with the aim of improving equity and reducing stigmatization for people who live with more than 6,000 rare diseases. WHAT ARE RARE DISEASES Rare diseases are pathologies or disorders that affect a small part of the population (less than 5 per 10,000 inhabitants) and[...]

03 Feb

Nanoligent, whoes founders are leaders of NANBIOSIS units, raises €1M in Series Seed financing

Barcelona, Spain – Milan, Italy, February 3rd, 2022 – Nanoligent SL, a biotech company specialized in the development of nanotechnology-based cancer treatments, today announces the completion of the first closing of a Seed financing round of €1M. The round has been led by members of Italian Angels for Growth, the largest network of business angels in Italy, through the investment vehicle Nanolinvest, and AVANTECA Partners, a Swiss privately held asset management firm, both specialized in supporting innovative early-stage life-science companies primarily in Europe. An equity campaign, is still ongoing on Doorway, an online investment platform, thus promising to provide additional funding[...]

11 Jan

The activity of Peptide T22 as antimicrobial drug opens new possibilities for the local control of bacterial infections related to tumors

Researchers of NANBIOSIS Units 1 and 18, from CIBER-BBN at the Institut de Biotecnologia i de Biomedicina (IBB-UAB) and the Institut de Recerca Sant Pau (IIB-Sant Pau) presents the finding of a significant antimicrobial activity in the targeting peptide T22, which is used for antitumor therapy directed against CXCR4 + stem cells, with clinical interest in more than 20 types of human cancer, including colorectal cancer. The study describes how said activity has a significant effect on several bacterial species of clinical importance: “we have detected antimicrobial activity associated with T22 and inhibition of biofilm formation on Escherichia coli, Staphylococcus[...]

18 Apr

Collaboration of two NANBIOSIS units in the Valorisation Project “ADVERT”

The Project ADVERT (Advanced Extracellular Vesicles for Enzyme Replacement Therapy) is a research valorisation project recently granted by CIBER. The project pursues to advance the development of extracellular vesicles as treatments for lysosomal diseases, specially to bring new therapies to treat FABRY disease. The ADVERT Project will count on the active particpation of two NANBIOSIS units of CIBER-BBN: Unit 20 of the ICTS NANBIOSIS at Vall d’Ebrón Hospital, led by Ibane Abasolo, who coordinates the project. Unit 1 Protein Production Platform (PPP), at the IBB-UAB, led by Neus Ferrer, throught the coordination in the project of José Luis Corchero. T[...]

U1-Protein Production Platform - PPP
• Read More

U3. Synthesis of Peptides Unit

Ciber bbn

U3. Synthesis of Peptides Unit

  • Scientific Director: Prof. Fernando Albericio albericio@ub.edu
  • Scientific Coordinator: Dr. Miriam Royo miriam.royo@iqac.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC

IQAC CSIC

Order request

U3. Peptides-Automatic synthesizer which can be operated at a range of scalesU3. Peptides-Automatic synthesizer which can be operated at a range of scales
U3. Peptides-System for acidolactic cleavage of the peptide resin boundby anhydrous HFU3. Peptides-System for acidolactic cleavage of the peptide resin boundby anhydrous HF

This Unit is coordinated by the Multivalent Systems for Nanomedicine goup at IQAC-CSIC and has the equipment necessary to provide services of synthesis of peptides at different scales (mg to g), purification, characterization, and post-synthesis modification, such as, conjugation to proteins and fluorescent. It counts with laboratories for synthesis and other to carry out modification of the peptides during and post synthesis labels. Also counts with a laboratory equipped with several preparative and analytical chromatography systems for purification and characterization. This facility benefits from the wide experience of Dr. Fernando Albericio an Dra. Miriam Royo in the design and synthesis of peptides with specific biological activity and the introduction of modifications necessary for these peptides to be bound to therapeutic nanoconjugates and other molecules, either to take advantage of the pharmacological activity of the peptide itself or to facilitate the introduction of nanoconjugates or other molecules into the cells in order to reach the therapeutic target. Its location allows the access to the rest of services of the IQAC-CSIC.

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U3. Services & Rates

Equipments

In addition, this unit has access to:

Active projects

Title Fundin: Organism Call: Funding source Role
ICTS-2017-10-CIBER-2 Acquisition and istallation of infrastrucuture to complemntUnis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivoExperiment Ministerio de Economía, Industria y Competitividad (MINECO) Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt) Coordinator
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017		 Coordinator

Other projects

Ref Title Funding Organism Unit Role
SAF2015-67476-R Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS) Ministerio de Economía y Competitividad Participant
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant

Publications

2016

  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U3

20 Jan

New nanoarchitectonics of RGD peptide developed using quatsomes as robust tool in tissue engineering.

Researchers of three groups of CIBER-BBN at CSIC and IBEC, have created a versatile platform based on hierarchically nanostructured RGD peptide using quatsomes, with proved enhanced cell adhesion. These findings, which arose within the framework of the intramural project of CIBER-BBN “Molecular Biointerfaces for cell guidance” (DynaMo4Vasc), open new possibilities for tissue engineering. The participation of two NANBIOSIS units were acknowledged in the publication of the research results: the synthesis of RGD derivatives were performed at NANBIOSIS U3 “Synthesis of peptides unit” of CIBER-BBN at IQAC−CSIC.  And the design and characterization of quatsomes were done at U6 of NANBIOSIS “Biomateria[...]

15 Nov

Happy Day of Chemistry! The role of Chemistry in a sustainable research in health

Today, November 15 is a day of celebration for us, the Day of the Chemistry in Spain! Chemistry is the science that studies matter, how it is composed, its properties and how its structures are transformed and, as matter is everything, including living beings and ourselves, we can say that chemistry is omnipresent and transversal in all areas surrounding us. Chemistry is everywhere, we ourselves are chemistry and our health and our life is chemistry. “Everything around us is chemistry in the environment, foods, what we use and what we touch every day. Our own body is a sophisticated complex[...]

27 Jul

1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection

During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]

28 Feb

Fabry Desease in the Rare Disease Day: A New Hope

WHY DO CELEBRATE TODAY THE INTERNATIONAL #RareDiseaseDay? 29 of February is a ‘rare’ date and February, a month with a ‘rare’ number of days, has become a month to raise awareness about rare diseases and their impact on patients’ lives.  Since 2008 thousands of events happen every year all around the world and around the last day of February with the aim of improving equity and reducing stigmatization for people who live with more than 6,000 rare diseases. WHAT ARE RARE DISEASES Rare diseases are pathologies or disorders that affect a small part of the population (less than 5 per 10,000 inhabitants) and[...]

03 Feb

Multivalent self-assembled platforms for the delivery of chemotherapeutic drugs

Twenty years ago, the 4 February was declared World Cancer Day with the global challenge of cancer would not be forgotten. Since then, huge progress has been made to understand, prevent, diagnose, and treat cancer. NANBIOSIS as an ICTS (Singular Scientific and Technical infrastructures) for biomedical research plays a very important role in the fight against cancer. Dr. Miriam Royo, who leads NANBIOSIS unit 3 of Synthesis of Peptide, explains one of the projects in which the ICTS is involved in relation with cancer therapy. The improvement of solubility and stability of clinically approved chemotherapeutic drugs still represent a big[...]

26 Feb

A more effective nanomedicine has been developed for the treatment of Fabry rare disease.

28 February: International Rare Disease Day This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work.The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future.The new drug improves on current treatments and helps reduce costs and improve patients’ quality of life. Barcelona, 26 February 2021.- The advance of nanomedicine opens up new possibilities in the development of drugs, such as the one recently developed for the rare disease Fabry, with improved efficacy compared to existing[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

27 Jan

Smart-4-Fabry final workshop

Next Wedneday, February 3, 2021 will take place the on-line event Smart-4-Fabry Final Workshop.   Smart-4-Fabry is a european project, coordinated by CIBER-BBN wich has been developed during four years. This project is a sign of cooperation at European level to boost nanomedicine development and translation to clinical stages. This project is also a clear example of the relevance of access to advanced research infrastructures as NANBIOSIS -ICTS. Four NANBIOSIS units have collaborated and contributed to Smart-4-Fabry development: U1 Protein Production Platform (PPP) at IBB-UABU3 Synthesis of Peptides Unit at IQAC-CSICU6 Biomaterial Processing and Nanostructuring Unit at ICMAB-CSICU20 In Vivo[...]

U3-Synthesis of Peptides Unit
• Read More

U6. Biomaterial Processing and Nanostructuring Unit

Ciber bbn

U6. Biomaterial Processing and Nanostructuring Unit

    • Scientific Director: Prof. Nora Ventosa ventosa@icmab.es 
    • Scientific Coordinator: Dr. Mariana Köber mkober@icmab.es
    • Technical Coordinator: José Amable Bernabé jabernabe@icmab.es
    • Entities: Instituto de Ciencia de Materiales de Barcelona ICMAB-CSIC
    • Address: Campus de UAB, 08193, Bellaterra, Barcelona, Spain
    • Phone: +34 935 801 853
    • Fax: +34 935 805 729
    • Web: ICMAB

ICMAB CSIC

Order request

U6. Compressed fluids based biomaterials processing platformU6. Compressed fluids based biomaterials processing platform
U6. Dynamic light scattering for particle size and Z potential measurementsU6. Dynamic light scattering for particle size and Z potential measurements
U6. Compressed fluids based biomaterials processingU6. Compressed fluids based biomaterials processing

Description

Located at the Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), in Barcelona, and under the coordination of Professor Jaume Veciana and Prof. Nora Ventosa, current directors of NANOMOL Group, which is a research group with wide expertise and recognized excellence in the synthesis, processing and study of molecular and polymeric materials with chemical, electronic, magnetic and biomedical properties.  It gathers several laboratories, perfectly equipped, to perform the mission of this facility: the development, characterization, and large-scale production of molecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano- and supramolecular structure. One example of Key-Enabling-Technology (KET) available in this unit is a simple one-step methodology, DELOS-SUSP, based on the use of compressed fluids (CF), such as CO2, to prepare particulate materials with precise and reproducible structural characteristics at micro-, nano- and supramolecular levels (size, shape, internal structural gradients, supra­molecular organization and crystalline purity). This example shows one of the singularities of this unit is that counts with CF–based plants at different scales, from mL to L, which allow process development by QbD and process scale-up.
The NANBIOSIS Unit 6 is works under the ISO9001 certification for standard quality control system
 




 




 



		
Services

		

			



FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE 
		
U6. Services & Rates

		
Equipments

		

			




		

		
		
	

		
		

		
Active projects

		

			


	






Title
Fundin: Organism
Call: Funding source 
Role







GA: 720942

SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry
Unión Europea (Comisión Europea)
H2020-NMBP-2016-2017
Coordinator




SAF2017-90810-REDI

Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II
Agencia Estatal de Investigación (AEI)
Acciones de dinamización  «REDES DE EXCELENCIA»

-ICTS 2017		
Coordinator







		

		
Other projects

		

			


	




Ref
Title
Funding Organism
Unit Role







PI15/00272
Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer.
Instituto de Salud Carlos III
Participant




H2020-MSCA-ITN-2014-642196
Integrated self-assembled SWITCHable systems and materials: towards responsive organic electronics - a multi-site innovative training action i-Switch
Unión Europea H2020
Participant




2014 SGR 17
Consolidation Research Group: Molecular Nanociènciai Materials Orgànics (NANOMOL)
Generalitat de Catalunya
Participant




CTQ2013-40480-R
Molecular Bio- and Electro-active materials for the improvement of health and social well-being (Be-Well)
MICINN
Participant




FP7-PEOPLE-2013-ITN nº 607721
Nanochemistry of molecular materials for 2-photon functional applications. Nano2Fun
Unión Europea
Participant




MAT2013-50036-EXP
Cell Surface Vessel Engineering Using Dynamic Molecular Bioinfecting (DYNAMO)
MINECO
Participant




RTC-2016-4567-1
Nanocapsules containing active ingredients for the topical treatment of dermatological diseases (NANO4DERM)
MINECO
Participant




RTC-2014-2183-S
Application of Quatsomes technology for the development of a new range of perfumed softeners with lower environmental impact
MINECO
Participant




201260E080
Self-assembly, Nanostructuring and Processing of Functional Organic Molecules and their Applications
Ministerio de Ciencia e Innovación
Participant




MAT2016-80826-R
Molecular materials and supramolecular organizations for therapy, diagnosis and tissue engineering (MOTHER)
MINECO
Participant




RTC-2014-2207-1
TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases
MINECO
Participant







		

		
Publications

		

			2016




    

  • Munoz-Gomez J.L., Monteagudo E., Lloveras V., Parella T., Veciana J., Vidal-Gancedo J.. Optimized polarization build-up times in dissolution DNP-NMR using a benzyl amino derivative of BDPA. RSC Advances. 2016;6(32):27077-27082.
    • 

  • Cordoba A., Hierro-Oliva M., Pacha-Olivenza M.A., Fernandez-Calderon M.C., Perello J., Isern B. et al. Direct Covalent Grafting of Phytate to Titanium Surfaces through Ti-O-P Bonding Shows Bone Stimulating Surface Properties and Decreased Bacterial Adhesion. ACS Applied Materials and Interfaces. 2016;8(18):11326-11335.
    • 

  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
    • 

  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.
    • 




		

		
		
	

		
		
News U6
12 May
NABIHEAL project launches website
The website for NABIHEAL, an EU-funded Horizon Europe project developing biomaterials for complex wound healing, is now online. The Horizon Europe project NABIHEALi project is coordinated by the Center for Biomedical Research Network (CIBER) at the Institute of Materials Science of Barcelona (ICMAB-CSIC). This project will apply one the “Cutting Edge Biomedical Solutions” of NANBIOSIS for the preparation of different nanoestructures with antimicrobial properties, required for the development of the final multifunctional wound healing biomaterials. This case will gather the expertise of two NANBIOSIS unit: NANBIOSIS U6 will produce and characterize these nanoestructures with antimicrobial properties, which will be tested in NANBIOSIS U16. Find out mor[...]
21 Mar
A discovery in one of the most aggressive cancers will allow more efficient diagnosis
The extracellular vesicles secreted by triple-negative breast cancer stem cells are markers of lung metastasis, according to a study carried out by researchers at CIBER. The work has been carried out by researchers from various CIBER-BBN groups (Bioengineering, Biomaterials and Nanomedicia), and CIBERONC (CIBER area focused on cancer) has participated in it. The research has been led by Joaquín Seras, from the Vall d’Hebron Research Institute (VHIR), a specialist in targeted drug therapies. Physicochemical EVs characterization and all the in vivo studies were performed by NANBIOSISunits of CIBER, specifically NTA analysis was carried out at Unit 6 of Biomaterial Processing[...]
20 Mar
Nanoparticles to modulate topography and ligand distribution at the nanoscale: impact on cell behavior
Doctor Marc Martínez from the Nanomol-Bio group – NANBIOSIS U6 from CIBER-BBN at ICMAB-CSIC, defended his PhD thesis “Nanoparticles to modulate topography and ligand distribution at the nanoscale: impact on cell behavior” on 9 March 2023 at ICMAB. he PhD thesis was supervised by Imma Ratera, Judith Guasch and Nora Ventosa from the Nanomol-Bio group at ICMAB-CSIC. Ana Paula Candiota Silveira, Scientific Coordinator of NANBIOSIS U25 was part of the Committee that evaluated the Thesis tooghether with Jesús Martínez de la Fuente, Instituto de Nanociencia y Materiales de Aragón (INMA-CSIC) (President),  and Anna Lagunas Targarona, Institut de Bioenginyeria de Catalunya (IBEC) (Vocal). As[...]
02 Feb
Advancing a novel nano-pharmaceutical towards clinical translation
Prof Nora Ventosa, Scientific Director of NANBIOSIS U6 “Biomaterial Processing and Nanostructuring Unit” from CIBER-BBN and ICMAB-CSIC) is hosting the Lecture on nano-pharmaceuticals: “Advancing a novel nano-pharmaceutical towards clinical translation” by Elisabet González, from Nanomol-Bio Group of ICMAB-CSIC and CIBER-BBN Monday, 13 February 202312 PM – 15 PMICMAB – Sala d’Actes Carles Miravitlles and ONLINE Registration and futher information Abstract: Nano-pharmaceuticals have the potential to drive the scientific and technological uplift, offering great clinical and socio-economic benefits to the society in general, industry and key stakeholders and patients. However, the translation of nano-pharmaceuticals from lab bench to an advanced stage of[...]
20 Jan
New nanoarchitectonics of RGD peptide developed using quatsomes as robust tool in tissue engineering.
Researchers of three groups of CIBER-BBN at CSIC and IBEC, have created a versatile platform based on hierarchically nanostructured RGD peptide using quatsomes, with proved enhanced cell adhesion. These findings, which arose within the framework of the intramural project of CIBER-BBN “Molecular Biointerfaces for cell guidance” (DynaMo4Vasc), open new possibilities for tissue engineering. The participation of two NANBIOSIS units were acknowledged in the publication of the research results: the synthesis of RGD derivatives were performed at NANBIOSIS U3 “Synthesis of peptides unit” of CIBER-BBN at IQAC−CSIC.  And the design and characterization of quatsomes were done at U6 of NANBIOSIS “Biomateria[...]
16 Jan
New European Project NABIHEAL in biomaterials for complex wound healing
The Horizon Europe project NABIHEAL, coordinated by the Center for Biomedical Research Network (CIBER) at the Institute of Materials Science of Barcelona (ICMAB-CSIC), was launched on 11-12 January 2023 in Barcelona with the first meeting of the international consortium, formed by 14 partners from 7 countries, including research centers, universities, and private companies.  This project will apply one the “Cutting Edge Biomedical Solutions” of NANBIOSIS for the preparation of different nanoestructures with antimicrobial properties, required for the development of the final multifunctional wound healing biomaterials. This case will gather the expertise of two NANBIOSIS unit: NANBIOSIS U6 will produce and[...]
24 Nov
“Preparation and characterization of SOFT Materials” Technical Seminar
Amable Bernabé, Tecnical Coordinator of NANBIOSIS U6: Biomaterial Processing and Nanostructuring Unit of CIBER-BBN and ICMAB-CSIC is giving a seminar on Preparation and Characterization of SOFT Materials. The seminar will tame place on Monday, 28 November 2020, at 12 PM at ICMAB in the Carles Miravitlles Seminar Hall, ” I will make a brief explanation about the equipment for the characterisation of particulate materials, type of samples that can be analysed, reports, etc… I will also talk about the equipment for processing materials with C” -explains Amable Bernabé.  Amable Bernabé joined the ICMAB-CSIC in 2004 as a research assistant working[...]
20 Oct
New edition of the course on characterization and preparation of particulate materials.
ICMAB-CSIC October 19th 2022 Amable Bernabé, from Nanbiosis U6 Biomaterial Processing and Nanostructuring Unit hosted from Monday, 3 October, to Wednesday, 5 October a course on “Characterization techniques for particulate materials”. The course counted with 10 participants from different CSIC centers. The course was an introduction to different techniques to characterize nanoparticles and other particulate matter, including the basic fundamentals of these techniques, sample preparation, practical examples and results interpretation.    It is the fifth edition of the course, which started in 2018. Amable Bernabé, technician from the Soft Materials Service, prepares and offers this course to all the CSIC community, so everyone who needs[...]

		
		
	

											

											U6-Biomaterial Processing and Nanostructuring Unit											

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U10. Drug Formulation

												

		
		
Ciber bbn


U10. Drug Formulation


    

  • 

      

    • Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
      • 

    • Scientific Coordinator: Dr. Idoia Gallego Garrido idoiagallego@hotmail.com
      • 

    • Entities: Universidad del País Vasco (UPV/EHU)
      • 

    • Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
      • 

    • Phone: +34 653593042
      • 

    • Fax: +34 945 013040
      • 

    • Web: NANOBIOCEL UPV/EHU
      • 

    

    • 









UPV-EHU






Order request

		
		
	

		
		
U10. Drug Formulation-Particle_size_analyzerU10. Drug Formulation-Particle_size_analyzer
U10. Drug Formulation-LOTE 4 CALCEINA 10X 2BISU10. Drug Formulation-LOTE 4 CALCEINA 10X 2BIS
U10. Drug Formulation- Dissolution_rate_determination_equipmentU10. Drug Formulation- Dissolution_rate_determination_equipment


Description


Located at the Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Campus of Alava in Vitoria. The Unit is led by Prof. José Luis Pedraz and consists of large laboratories for cell culture, chromatography equipment, sample preparation and characterization, and one specific for scale preparation of pharmaceutical formulations. Recently the group has incorporated 3D bioprinters of the last generation with different technologies based on extrusion, inkjet, among others. It has also incorporated self-assembly equipment of nanoparticles based on microfluidic technologies.


This Unit can design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA, and vaccines using different methodologies based on micro and nano-medicine and the latter technology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this Unit. It counts on the most advanced equipment for micro and nanoencapsulation.


The Unit aims to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.


The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit10 counts with the most advanced equipment to cover the development for all the steps of the process.


One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency 



		
Services

		

			



FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE



		
U10. Services & Rates

		
Equipments

		

			




		

		
		
	

		
		

		
Active projects

		

			


	






Title
Fundin: Organism
Call: Funding source 
Role







RTC-2016-4770-1

Development of a new bioadhesive for the treatment of Pterigium. Biotape


Ministerio de Economía, Industría y Competitividad (MINECO)
Retos Colaboración 2016
Partner




RTC-2016-5451-1

Development of Bioprinting and Bioink systems for cartilage and bone repair


Ministerio de Economía, Industria y Competitividad (MINECO)
Retos Colaboración 2016
Partner




GA: 783132

POSITION-II “A pilot line for the next generation of smart catheters and implants”


Electronic Component Systems for European Leadership Joint Undertaking (JU) - ECSEL JU
H2020-ECSEL-2017-1-IA-two-stage
Partner




GA: 645991

DRIVE – Diabetes-Reversing Implants for Enhanced viability and long-term efficacy
Unión Europea (Comisión Europea)
H2020-NMP-2014-two-stage
Partner




SAF2017-90810-REDI

Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II
Agencia Estatal de Investigación (AEI)
Acciones de dinamización  «REDES DE EXCELENCIA»

-ICTS 2017		
Coordinator







		

		
Other projects

		

			


	




Ref
Title
Funding Organism
Unit Role







RTC-2016-4770-1
DEVELOPMENT OF A NEW BIOADHESIVE FOR PTERIGIUM SURGERY. BIOTAPE
MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD.
Participant




RTC-2016-5451-1
DEVELOPMENT OF BIOIMPRESSION SYSTEMS AND BIOTINES FOR THREE-DIMENSIONAL CARTILAGE AND BONE REGENERATION
MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD.
Participant




RTC-2015-3303-1
Lipid solid nanoparticles for subcutaneous administration of antitumor marine compounds - UNDERLIPIDS
MINISTERIO DE ECONOMIA Y COMPETITIVIDAD








		

		
Publications

		

			2016


    

  • Grijalvo S., Puras G., Zarate J., Pons R., Pedraz J.L., Eritja R. et al. Nioplexes encapsulated in supramolecular hybrid biohydrogels as versatile delivery platforms for nucleic acids. RSC Advances. 2016;6(46):39688-39699.
    • 

  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Fleischer A. et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. International Journal of Pharmaceutics. 2016;498(1-2):263-273.
    • 

  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Bachiller D. et al. Stability study of sodium colistimethate-loaded lipid nanoparticles. Journal of Microencapsulation. 2016;33(7):636-645.
    • 

  • Garcia-Orue I., Gainza G., Gutierrez F.B., Aguirre J.J., Evora C., Pedraz J.L. et al. Novel nanofibrous dressings containing rhEGF and Aloe vera for wound healing applications. International Journal of Pharmaceutics. 2016;:-.
    • 

  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The role of helper lipids in the intracellular disposition and transfection efficiency of niosome formulations for gene delivery to retinal pigment epithelial cells. International Journal of Pharmaceutics. 2016;503(1-2):115-126.
    • 

  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The influence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain. Biomaterials. 2016;77:267-279.
    • 




		

		
		
	

		
		
News U10
23 Nov
Three articles acknoledging NANBIOSIS contribution awarded at the Bioaraba Research and Innovation Conference
Researchers of NANBIOSIS U10 “Drug Formulation” – NanoBiocel research group from CIBER-BBN and UPV/EHU receives 3 awards in the category of Best International Articles at the annual Bioaraba Research and Innovation Conference. On 4 November, the Bioaraba Health Research Institute held its XXIII Research and Innovation Conference in Vitoria. This important annual forum held in [...]
27 Oct
II Scientific Communication course
On October 18 and 19, was held the second course on Social Communication of Science, orgnized by NANBIOSIS U10 Drug Formulation Unit -(NanoBioCell Group of CIBER-BBN and UPV-EHU, this year entitled “Tools for the social communication of science“. The course aimed to provide doctoral students with communication with tools to be employed in their work [...]
09 Oct
The sprint of the European Project Moore4medical
The NanoBioCel group of the CIBER BBN, which also runs NANBIOSIS U10 Drug Formulation unit , organized the Workshop #6 of the Moore4medical European project at the Alava Technology Park on October 4, 5 and 6 The Central Building of the Álava Technology Park hosted the ‘Workshop #6’ of the European project which. 80 people [...]
29 Apr
CRISPR technologies for Cystic Fibrosis treatment
Cystic fibrosis is an inherited genetic disease that mainly affects the lungs and the digestive system On April 6, the first meeting was held, on the one hand, with people with Cystic Fibrosis and the Euskadi Cystic Fibrosis Association (Arnasa) and, on the other, with the NanoBioCel research group of the CIBER-BBN and the University [...]
05 Apr
1st Meeting with Cystic Fibrosis Patiens (NanoBioCel -ARNASA)
Cystic Fibrosis is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. It is a genetic, degenerative and chronic disease, with a population incidence is 1 in 5,000, so it is considered among the so called “Rare Diseases” The most common symptoms are continuous colds, repeated infections, decreased lung capacity, impossibility of fat absorption and [...]
22 Mar
The results of POSITION II highlighted by CORDIS: A pan-European alliance for the next generation of smart catheters
In the picture: microencapsulated cardiospheres 10X Captured Brightfield with DM_RGB_Brightfield with DM The European project POSITION-II has been selected for publication in the ‘Results in Brief’ section of the Community Research and Development Information Service (CORDIS) website. CORDIS is the European Commission’s primary source of results from the projects funded by the EU’s framework programmes [...]
15 Feb
AWARDS of the Academy of Pharmacy of Castilla y León 2021 to  researchers from NANBIOSIS U10
The leader of the NanoBioCell Group form CIBER-BBN and UPV/EHU, Jose Luis Pedraz, and the reaearches Laura Saenz del Burgo and Markel Lafuente have received the 2021 Award from the Academy of Pharmacy of Castilla y León, on February 4, at the city ​​of Salamanca, for the work entitled: “Design and Characterization of a biotin [...]
13 Jan
Best Emergeging Researcher Award  in the Biomedical Area to Edorta Santos
Edorta Santos Vizcaíno has been awarded as Best Emerging Researcher in the biomedical area by the Bioaraba Health Research Institute in the XXII edition of the Research and Innovation Conference. This award aims to recognize the work of researchers under the age of 40 who carry out their research activity in any public center of [...]
26 Nov
New Equipment available for the Regenerative Medicine Research Line of the U10 of NANBIOSIS
The Unit 10 of Drug Formulation of the ICTS NANBIOSIS coordinated by the CIBER-BBN NanoBioCel group directed by Jose Luis Pedraz, which belongs to the University of the Basque Country, has been present at the signing of the agreement that gives support by the Provincial Council of Alava within the framework of the Advance Pharma [...]
14 Oct
Results of the POSITION-II Project “A pilot line for the next generation of smart catheters and implants”
Cáceres, October 14th, 2021 POSITION II has received funding within the Electronic Components and Systems for European Leadership Joint Undertaking (ECSEL JU) in collaboration with the European Union’s H2020 Framework Programme (H2020/2014-2020) and National Authorities, under grant agreement Ecsel-783132-Position-II-2017-IA. It promotes innovation in smart medical instruments and focuses in the next generation of smart catheters [...]

		
		
	

											

											U10-Drug Formulation											

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U18. Nanotoxicology Unit

												

		
		
Ciber bbn


U18. Nanotoxicology Unit


    

  • 

      

    • Scientific Director: Prof. Ramón Mangues rmangues@santpau.cat
      • 

    • Scientific Coordinator: Dra.Isolda Casanova ICasanova@santpau.cat
      • 

    • Entities: Institut de Recerca. Hospital de la Santa Creu i Sant Pau 
      • 

    • Address: Hospital Santa Pau. c/Sant Antoni M. Claret, 167, 08025, Barcelona
      • 

    • Phone: +34 935 537 918
      • 

    • Web: WEB
      • 

    

    • 









 
SAN-PAU






Order request

		
		
	

		
		
U18.-Cell culture unit  air flow cabiner for performing in vitro assaysU18.-Cell culture unit  air flow cabiner for performing in vitro assays
U18.-Animal facility-SPF conditions II for in vivo experimentsU18.-Animal facility-SPF conditions II for in vivo experiments
U18.- Animal Facility-Inmunossupresed mouseU18.- Animal Facility-Inmunossupresed mouse


Description


This Unit is located in the Hospital de la Santa Creu i Sant Pau, in Barcelona, and is coordinated by Dr. Ramón Mangues, PI of the Oncogenesis and Antitumor Drug Group. The main objective of the Nanotoxicology Unit is to assess the toxicity of new drugs, nanoparticles or nanotechnology-based biomaterials in in vitro and in vivo systems, with the goal of optimizing lead compounds and identifying those with the highest probability of success in the preclinical programme due to their greater safety and tolerability or reduced toxicity. The Unit has rooms equipped for cell culture, for cryopreservation of samples and cell lines, and for sample preparation and analysis and animal facilities for in vivo experimentation.


Equipment: The Unit has access to flow cytometers, sorters, confocal microscope and other equipment of the Platforms available at the Hospital Research Institute as well as housing facilities for small rodents (rat and mouse).



		
Services

		

			


FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE


		
U18. Services & Rates

		
Equipments

		

			


		

		
		
	

		
		

		
Active projects

		

			
TitleFundin: OrganismCall: Funding source Role

    
    
	
	
ICTS-2017-10-CIBER-2Acquisition and istallation of infrastrucuture to complemntUnis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivoExperimentMinisterio de Economía, Industria y Competitividad (MINECO)Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt)Coordinator
SAF2017-90810-REDIStrategic Promotion and coordinated management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)Acciones de dinamización  «REDES DE EXCELENCIA»
-ICTS 2017Coordinator

    


		

		
Other projects

		

			
RefTitleFunding OrganismUnit Role

    
    
	
	
PI15/00378Intelligent nanoconjugates for targeted therapy of metastatic colorectal cancer (CRC)Instituto de Salud Carlos IIIWorking package
PIE15/00028Targeted nanocongugates for the selective elimination of stem cells in disseminated cancerInstituto de Salud Carlos IIIWorking package
PI15/00272Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer.Instituto de Salud Carlos IIIParticipant
CP15/00163Maria Virtudes Céspedes Navarro Contracts Miguel Servet Type IInstituto de Salud Carlos IIIWorking package
CD14/00055Contract SARA BORRELLInstituto de Salud Carlos IIIWorking package
Marato 416/C/2030TV32013-132031Genotoxic nanoparticles targeting colorectal cancer stem cellsMarato TV3Participant

    


		

		
Publications

		

			2016


    

  • Cespedes M.V., Guillen M.J., Lopez-Casas P.P., Sarno F., Gallardo A., Alamo P. et al. Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gem;citabine, in pancreatic adenocarcinoma mouse models. DMM Disease Models and Mechanisms. 2016;9(12):1461-1471.
    • 

  • Rueda F., Cespedes M.V., Sanchez-Chardi A., Seras-Franzoso J., Pesarrodona M., Ferrer-Miralles N. et al. Structural and functional features of self-assembling protein nanoparticles produced in endotoxin-free Escherichia coli. Microbial Cell Factories. 2016;15(1):-.
    • 

  • Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova I et al. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models.Nanomedicine : nanotechnology, biology, and medicine. 2016;12(7):-.
    • 

  • Cespedes M.V., Fernandez Y., Unzueta U., Mendoza R., Seras-Franzoso J., Sanchez-Chardi A. et al. Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs. Scientific Reports. 2016;6:-.
    • 

  • Vazquez E., Mangues R., Villaverde A.. Functional recruitment for drug delivery through protein-based nanotechnologies. Nanomedicine. 2016;11(11):1333-1336.
    • 

  • Serna N., Cespedes M.V., Saccardo P., Xu Z., Unzueta U., Alamo P. et al. Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016;12(5):1241-1251.
    • 

  • Cano-Garrido O, Céspedes MV, Unzueta U, Saccardo P, Roldán M, Sánchez-Chardi A et al. CXCR4(+)-targeted protein nanoparticles produced in the food-grade bacterium Lactococcus lactis.Nanomedicine (London, England). 2016;11(18):-.
    • 

  • Rueda F., Gasser B., Sanchez-Chardi A., Roldan M., Villegas S., Puxbaum V. et al. Functional inclusion bodies produced in the yeast Pichia pastoris. Microbial Cell Factories. 2016;15(1):-.
    • 

  • Pesarrodona M., Fernandez Y., Foradada L., Sanchez-Chardi A., Conchillo-Sole O., Unzueta U. et al. Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria. Biofabrication. 2016;8(2):-.
    • 



		

		
		
	

		
		
News U18
28 Sep
Nanoligent raised €2.8 M and completed Seed round financing with support of i&i Biotech Fund
September 27th 2022 – Nanoligent SL, a Spanish biotech company specialized in the development of cancer treatments based on unique protein conjugates, today announces the completion of a Seed financing round of total € 2.8 M. The final closing of the Seed round consists of € 1 M investment by i&i Biotech Fund I (i&i Bio), an early-stage Life Science fund with teams in Luxemburg and Prague which is backed by the European Investment Fund. i&i Bio joined previous Nanoligent investors, Italian Angels for Growth, the largest network of business angels in Italy, and AVANTECA Partners, a Swiss privately held[...]
02 May
Wide representation of NANBIOSIS research in NALS 2022 and best Oral Presentation to Eloi Parladé
During the last 27-29 April, the 3rd International Conference on Nanomaterials Applied to Life Sciences 2022 (NALS 2022) has taken place in the Excellence Campus of Universidad de Cantabria in Santander (Spain), organized by the University of Cantabria and Institute Valdecilla-IDIVAL. NALS 2022 has been a multidisciplinary conference series sharing new results and ideas in the fields of biosensors, lab on a chip, drug delivery nanopharmacy. nanobiotechnology, intelligent nanomaterials, magnetic materials, nanotoxicity, antimicrobials, novel applications of 3d bioprinting and nanoimaging. NANBIOSIS has been represented at this edition by members of several of its units, among them we must highlight the set of four ora[...]
03 Feb
Nanoligent, whoes founders are leaders of NANBIOSIS units,  raises €1M in Series Seed financing
Barcelona, Spain – Milan, Italy, February 3rd, 2022 – Nanoligent SL, a biotech company specialized in the development of nanotechnology-based cancer treatments, today announces the completion of the first closing of a Seed financing round of €1M. The round has been led by members of Italian Angels for Growth, the largest network of business angels in Italy, through the investment vehicle Nanolinvest, and AVANTECA Partners, a Swiss privately held asset management firm, both specialized in supporting innovative early-stage life-science companies primarily in Europe. An equity campaign, is still ongoing on Doorway, an online investment platform, thus promising to provide additional funding[...]
29 Oct
Dr Ramón Mangues, new member of the Royal Academy of Pharmacy of Catalonia
Dr. Ramon Mangues, head of the Oncogenesis and Antitumor Group and Scientific Director of NANBIOSIS U18 Nanotoxicology Unit of CIBER-BBN at the Sant Pau Research Institute, has been recently elected as a new member of the Royal Academy of Pharmacy of Catalonia. The celebration will take place on November 8 at 7 pm, at the headquarters of the RAFC, (Royal Academy of Pharmacy of Catalonia) which was the headquarters of the old Hospital de la Santa Cruz since the 15th century, located at Calle del Hospital, 56, in Barcelona. During the event, Dr. Mangues will read his admission speech “Selectiv[...]
16 Mar
Development of a protein-only drug delivery system for sustained release
The Nanotoxicology Unit of CIBER-BBN ICTS NANBIOSIS (u18-nanotoxicology-unit), led by Ramon Mangues at the Research Institute of the Hospital de Sant Pau and the NABIOSIS (nanbiosis.es)Protein Production Platform (u1-protein-production-platform-ppp) led by Antonio Villaverde and Neus Ferrer Miralles of the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona, have participated in the development of a novel drug delivery system able to achieve sustained release of proteins with intrinsic antitumor activity. This delivery system consists on inclusion bacterial bodies formed by recombinant fusion proteins that precipitate while being expressed in bacteria, acquiring an amyloid structure, but remaining functional. Thus,[...]
25 Feb
An Auristatin-based nanoconjugate reduces leukemia burden in a disseminated AML model
Researchers of the Nanotoxicology Unit of the the CIBER-BBN ICTS NANBIOSIS (u18-nanotoxicology-unit), leaded by Ramon Mangues and Isolda Casanova at the Research Institute of the Hospital de Sant Pau and of the NANBIOSIS (nanbiosis.es) Protein Platform (u1-protein-production-platform-ppp) leaded by Antonio Villaverde and Neus Ferrer Miralles of the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona, have developed a novel protein-Auristatin nanoconjugate that specifically targets CXCR4-overexpressing acute myeloid leukemia (AML) cells. It selectively accumulates in target cancer cells expressing this receptor and deliver the toxin Auristatin within their cytosol. There, Auristatin potently blocks microtubule polymerization, provoking mitotic catastrophe,[...]
21 Feb
A nanotoxin targeting the receptor CXCR4 blocks lymphoma dissemination
Researchers at the Nanotoxicology Unit of CIBER-BBN ICTS NANBIOSIS (u18-nanotoxicology-unit), led by Ramon Mangues and Isolda Casanova of the Research Institute at the Hospital de Sant Pau and the Researchers of the NANBIOSIS (nanbiosis.es) Protein Production Platform (u1-protein-production-platform-ppp) led by Antonio Villaverde and Neus Ferrer Miralles of the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona, have participated in the development of a novel protein nanoparticle that incorporates the Exotoxin of the bacteria Pseudomonas aeruginosa, capable of targeting lymphoma cells that overexpress the CXCR4 receptor. They internalize selectively in target cancer cells through CXCR4 receptor-mediated endocytosis du[...]
15 Feb
Identification of a novel nanotherapy active in cancer cells resistant to chemotherapy
Researchers of the Nanotoxicology Unit (u18-nanotoxicology-unit) led by Ramon Mangues and Isolda Casanova at the Research Institute of the Hospital de Sant Pau and the Protein Production Platform (u1-protein-production-platform-ppp), led by Antonio Villaverde and Neus Ferrer Miralles of the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona, both belonging to the ICTS NANBIOSIS (nanbiosis.es) of the CIBER-BBN, have participated in the production of a novel Nanotoxin capable of selectively killing cancer cells which became resistant to chemotherapy. Development of cancer resistance frequently associates with the overexpression of the CXCR4 receptor. It is known that chemotherapy kills cancer[...]

		
		
	





											

											U18-Nanotoxicology Unit											

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U20. In Vivo Experimental Platform

												

		
		
Ciber bbn


U20. In Vivo Experimental Platform









U20. logo FVPP
CIBBIM-Nanomedicina Vall d'HebronVall d´Hebrón_U20,U18






Order request

		
		
	

		
		
U.20-Experiment in VIVO IVISU.20-Experiment in VIVO IVIS
U.20-MacroFluoU.20-MacroFluo
U.20- In vivo monitoring by bioluminescence and fluorescente imagingU.20- In vivo monitoring by bioluminescence and fluorescente imaging


Description


Located at the Valld’Hebron Research Institute (VHIR) in Barcelona, U20 In vivo Experimental Platform has three different sections, a Molecular Imaging section for in vivo, ex vivo and in vitro imaging studies (fluorescence, bioluminescence and X-rays), a preclinical animal model section and a preclinical histology section. All three sections are included within the Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine.


This unit is leadedby Dr. Ibane Abasolo (Head of FVPR) and supervised by the directorof CIBBIM-Nanomedicine, Dr. Simó Schwartz Jr. Its mission is to offer products and services for the preclinical proof-of-concept validation of therapeutic compounds and biomarkers with potential clinical applications. One of the distinguishing features of this unit is that basic preclinical studies including toxicology, histopathology and efficacy treatments are complemented with non-invasive optical imaging technologies. In vivo bioluminescence and fluorescence imaging allows monitoring of living mice longitudinally, offering real time insight into treatment efficacy, whole-body biodistribution and target mechanisms. Although in Spain there are other institutions with similar equipment, this is the only case in which imaging services can be combined with specifically devoted animal models.



		
Services

		

			



FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE



		
U20. Services & Rates

		
Equipments

		

			




		

		
		
	

		
		

		
Active projects

		

			


	






Title
Fundin: Organism
Call: Funding source 
Role







ICTS-2017-10-CIBER-2

Acquisition and istallation of infrastrucuture to complemnt Unis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivo Experiment
Ministerio de Economía, Industria y Competitividad (MINECO)
Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt)
Coordinator




GA: 720942

SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry
Unión Europea (Comisión Europea)
H2020-NMBP-2016-2017
Coordinator




SAF2017-90810-REDI

Strategic Promotion and coordinated

 management of Nanbiosis: Pronanbiosis II		
Agencia Estatal de Investigación (AEI)
Acciones de dinamización  «REDES DE EXCELENCIA»

-ICTS 2017		
Coordinator







		

		
Other projects

		

			


	




Ref
Title
Funding Organism
Unit Role







RTC-2014-2207-1
TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases
MINECO
Participant







		

		
Publications

		

			2016


    

  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.
    • 

  • Pesarrodona M., Fernandez Y., Foradada L., Sanchez-Chardi A., Conchillo-Sole O., Unzueta U. et al. Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria. Biofabrication. 2016;8(2):-.
    • 

  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
    • 

  • Cespedes M.V., Fernandez Y., Unzueta U., Mendoza R., Seras-Franzoso J., Sanchez-Chardi A. et al. Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs. Scientific Reports. 2016;6:-.
    • 




		

		
		
	

		
		
News U20
21 Mar
A discovery in one of the most aggressive cancers will allow more efficient diagnosis
The extracellular vesicles secreted by triple-negative breast cancer stem cells are markers of lung metastasis, according to a study carried out by researchers at CIBER. The work has been carried out by researchers from various CIBER-BBN groups (Bioengineering, Biomaterials and Nanomedicia), and CIBERONC (CIBER area focused on cancer) has participated in it. The research has been led by Joaquín Seras, from the Vall d’Hebron Research Institute (VHIR), a specialist in targeted drug therapies. Physicochemical EVs characterization and all the in vivo studies were performed by NANBIOSISunits of CIBER, specifically NTA analysis was carried out at Unit 6 of Biomaterial Processing[...]
28 Feb
Rare diseases international day 2023: some NANBIOSIS contributions
Today is the international day of rare diseases, a day to raise awareness and instigate change for people living with a rare disease. From NANBIOSIS we want to sume to this celebration and higtligh our commitment to helping people with rare diseases through research. Dr. Ibane Abasolo, Scientific Director of NANBIOSIS U20, was at the WORLDSymposia conference last week in Orlando (FL, USA), where the latest advances in preclinical study and clinic of lysosomal storage diseases were explained. There, she presented the results obtained in the Smart4Fabry project coordinated by the CIBER-BBN where nanoliposomes were developed for the treatment of[...]
27 Jul
1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection
During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]
06 Apr
Targeting of the breast cancer stem cells to improve the treatment of triple negative breast cancer
On April 1st PhD candidate Patricia Cámara Sánchez defended her doctoral thesis entitled “Targeting of the breast cancer stem cells to improve the treatment of triple negative breast cancer“, where ICTS-Nanbiosis Unit 20 participated in the in vivo assays. The thesis was supervised by Dr. Ibane Abasolo  (scientific director of Unit 20 from CIBER-BBN and VHIR). Nanbiosis was also present within the jury, with Dr. Ana Paula Candiota (scientific coordinator of Unit 25 from CIBER-BBN and UAB) acting as secretary. Patricia Cámara graduated as biochemist, did the master’s degree in Translational Biomedical Research from VHIR-UAB. Shortly after, started the PhD, which was aimed[...]
28 Mar
New equipment installed in NANBIOSIS U20
NANBIOSIS, U20. In Vivo Experimental Platform, led by Dr. Ibane Ibasolo, has been updated and improved as a result of its participation in the project FICTS1420-20, selected by the MICINN for co-financing by the FEDER Program in ICTS 2014-2020 (Equipment for setting standardized immunotoxicology assays for the U20 -NANBIOSIS I17 Action of the Investment Plan-)[...]
20 Mar
The efficacy of nanoparticles combined with chemotherapy against pancreatic cancer
Pancreatic ductal adenocarcinoma is a highly devastating orphan disease with poor prognosis even when diagnosed early (The survival rate after 5 years (< 5%) has not changed over the last 30 years, despite tremendous research efforts) The european project NoCanTher, in wich participates NANBIOSIS U20 of (VHIR and CIBER-BBN) is a nanotechnology-based approach aimed to scale-up under GMP conditions and evaluate a nanoformulation for a combined therapy with chemotherapy against this pancreatic cancer. The international clinical study, carried out in the framework of the project is now incorporating the first pacient in Spain with this type of nanotherapy. The clinica[...]
08 Mar
Open Call Focus on Innovative MedTech using Nanotechnology
Start-ups / SMEs! Are you working on innovative medical products using nanotechnology? This is your call for development and marketing solutions! Last week took place the SAFE-N-MEDTECH Open Call on line info session with the idea to present the open call with a bit more detail. A few presentations and specially a time for questions and answers were organized by Anaïs Le Corber, Network Manager of CEBERG, the council of European Bioregions, partner of the project. The webinar was recorded and it is available here: First of all, Angel del Pozo, Coordinator of the SAFE-N-MEDTECH, gave an insight of t[...]
28 Feb
Fabry Desease in the Rare Disease Day: A New Hope
WHY DO CELEBRATE TODAY THE INTERNATIONAL #RareDiseaseDay? 29 of February is a ‘rare’ date and February, a month with a ‘rare’ number of days, has become a month to raise awareness about rare diseases and their impact on patients’ lives.  Since 2008 thousands of events happen every year all around the world and around the last day of February with the aim of improving equity and reducing stigmatization for people who live with more than 6,000 rare diseases. WHAT ARE RARE DISEASES Rare diseases are pathologies or disorders that affect a small part of the population (less than 5 per 10,000 inhabitants) and[...]

		
		
	

											

											U20-In Vivo Experimental Unit											

												
												•
												Read More